文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤放疗联合肿瘤电场治疗的剂量学初步结果

Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
PubMed 文献 · Radiat Oncol · 2020-04-19

本研究基于PriCoTTF-I期试验前7例胶质母细胞瘤患者,利用CBCT数据评估非共面IMRT与同步TTFields的剂量学影响。结果显示电极阵列导致头皮最高剂量区过量<8.5%处方剂量,CTV因衰减导致的低剂量限于2.0%(D95及等效均匀剂量)。阵列放置变化未致临床显著剂量偏差,证实同步治疗可行性。

要点

  • 电极阵列致头皮过量<8.5%处方剂量,CTV低剂量≤2.0%。
  • 阵列重复放置位置变化未引起临床显著剂量偏差。
  • 剂量学角度支持放疗同步TTFields可行。

核心结论

  • 从剂量学角度,电极阵列所致CTV剂量偏差在前7例患者中无临床意义,证实辅助放化疗同步TTFields可行。

研究设计与样本

  • 采用PriCoTTF-I期试验前7例患者的CBCT数据进行预设的剂量学验证与剂量累积分析,并几何分析治疗全程所用换能器阵列。

主要发现

  • 与无电极计划相比,头皮最初2mm内及1cm²外深层最高剂量区过量低于处方剂量的8.5%。
  • CTV因电极衰减导致的低剂量限于2.0%(以D95和等效均匀剂量计)。
  • 主成分分析显示阵列放置变异在额、枕、左、右方向第一主成分标准差分别为1.06cm、1.23cm、0.96cm、1.11cm。
  • 第二主成分标准差分别为0.70cm、0.71cm、0.79cm、0.68cm,患者间变异无差异(p>0.8,Kruskal-Wallis检验)。
  • 阵列移动减弱了电极的剂量学效应。

临床怎么用

  • 临床可依据CBCT图像引导评估电极阵列位置,并采用Boltzmann方程求解器或蒙特卡洛引擎重算剂量以验证。

局限性

  • 仅为前7例患者的初步剂量学结果,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma is a rapidly proliferating tumor. Patients bear an inferior prognosis with a median survival time of 14-16 months. Proliferation and repopulation are a major resistance promoting factor for conventionally fractionated radiotherapy. Tumor-Treating-Fields (TTFields) are an antimitotic modality applying low-intensity (1-3 V/cm), intermediate-frequency (100-300 kHz) alternating electric-fields. More recently interference of TTFields with DNA-damage-repair and synergistic effects with radiotherapy were reported in the preclinical setting. This study aims at examining the dosimetric consequences of TTFields applied during the course of radiochemotherapy. METHODS: Cone-beam-computed-tomography (CBCT)-data from the first seven patients of the PriCoTTF-phase-I-trial were used in a predefined way for dosimetric verification and dose-accumulation of the non-coplanar-intensity-modulated-radiotherapy (IMRT)-treatment-plans as well as geometric analysis of the transducer-arrays by which TTFields are applied throughout the course of treatment. Transducer-array-position and contours were obtained from the low-dose CBCT's routinely made for image-guidance. Material-composition of the electrodes was determined and a respective Hounsfield-unit was assigned to the electrodes. After 6D-fusion with the planning-CT, the dose-distribution was recalculated using a Boltzmann-equation-solver (Acuros XB) and a Monte-Carlo-dose-calculation-engine. RESULTS: Overdosage in the scalp in comparison to the treatment plan without electrodes stayed below 8.5% of the prescribed dose in the first 2 mm below and also in deeper layers outside 1cm2 at highest dose as obtained from dose-volume-histogram comparisons. In the clinical target volume (CTV), underdosage was limited to 2.0% due to dose attenuation by the electrodes in terms of D95 and the effective-uniform-dose. Principal-component-analysis (PCA) showed that the first principal-position-component of the variation of repeated array-placement in the direction of the largest variations and the perpendicular second-component spanning a tangential plane on the skull had a standard deviation of 1.06 cm, 1.23 cm, 0.96 cm, and 1.11 cm for the frontal, occipital, left and right arrays for the first and 0.70 cm, 0.71 cm, 0.79 cm, and 0.68 cm, respectively for the second-principal-component. The variations did not differ from patient-to-patient (p > 0.8, Kruskal-Wallis-tests). This motion led to a diminution of the dosimetric effects of the electrodes. CONCLUSION: From a dosimetric point of view, dose deviations in the CTV due to transducer-arrays were not clinically significant in the first 7 patients and confirmed feasibility of combined adjuvant radiochemotherapy and concurrent TTFields. PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. DRKS-ID: DRKS00016667. Date of Registration in DRKS: 2019/02/26. Investigator Sponsored/Initiated Trial (IST/IIT): yes. Ethics Approval/Approval of the Ethics Committee: Approved. (leading) Ethics Committee Nr.: 18-8316-MF, Ethik-Kommission der Medizinischen. Fakultät der Universität Duisburg-Essen. EUDAMED-No. (for studies acc. to Medical Devices act): CIV-18-08-025247.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Guberina N, Pöttgen C, Kebir S, et al. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. Radiat Oncol. 2020. PMID: 32307022. doi:10.1186/s13014-020-01521-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。